EGFR and non-small cell lung carcinoma: Based on their clinical significant benefits for NSCLC patients with EGFR T790M acquired drug-resistance mutation, United States Food and Drug Administration (FDA) has awarded compounds 7 and 8 “Breakthrough Therapy” designations in 201419.